This study explored the synergistic anti-tumor effects of CD19 combined with CD22 or CD20 dual-target CAR T-cell therapy in hematologic malignancies, and its preliminary results showed that CD19 combined with CD22 CAR T-cell therapy had a higher partial response rate in the treatment of hematologic malignancies than CD19 combined with CD20. This evidence concerns the gene CD19 and neoplasm.